SCHEMBL112244

SCHEMBL112244

Cc1cncc(Cl)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31171067 1.00
Cyanide SCHEMBL28048181 0.93 HCAR2 (0.39)
Formamide SCHEMBL28048134 0.87 HCAR2 (0.39)
Formic Acid SCHEMBL27869530 0.87 HCAR2 (0.44)
SCHEMBL197638 0.78
SCHEMBL24225 0.78
Hydrochloric Acid SCHEMBL6069542 0.76
SCHEMBL28044800 0.76
SCHEMBL30129770 0.76
Water SCHEMBL28044737 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 623 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112358487-B Lappaconitine derivative, and preparation method and application thereof 中国科学院新疆理化技术研究所 2023-08-25 CN claimed
WO-2022099937-A1 LAPPACONITINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 中国科学院新疆理化技术研究所 2022-05-19 WO claimed
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 EP claimed
US-9670208-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-06-06 US claimed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 EP claimed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 US claimed
WO-2015103137-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-07-09 WO claimed
EP-2419405-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS Theravance, Inc. (US) 2012-02-22 EP claimed
WO-2010120910-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS THERAVANCE, INC. (US) 2010-10-21 WO claimed
US-20100267743-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS THERAVANCE BIOPHARMA R&D IP, LLC 2010-10-21 US claimed
EP-4400502-A2 TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Shionogi & Co., Ltd (JP) 2024-07-17 EP disclosed
US-20240228472-A1 HETEROCYCLIC COMPOUND AND HARMFUL-ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2024-07-11 US disclosed
US-20240228472-A1 HETEROCYCLIC COMPOUND AND HARMFUL-ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2024-07-11 US disclosed
WO-2024130411-A1 PROTEASE INHIBITORS AND METHODS OF USING SAME VARIATIONAL AI INC. (CA) 2024-06-27 WO disclosed
WO-2024102989-A1 NON-PEPTIDIC SARS-COV-2 MAIN PROTEASE INHIBITORS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2024-05-16 WO disclosed
EP-0438691-A1 Process for the preparation of substituted 2-chloropyridines BAYER AG (DE) 1991-07-31 EP disclosed
US-5010201-A Process for the preparation of substituted 2-chloropyridines BAYER AKTIENGESELLSCHAFT (DE) 1991-04-23 US disclosed
EP-0370317-A1 Process for the preparation of substituted 2-chloropyridines BAYER AG (DE) 1990-05-30 EP disclosed
US-4897488-A Process for the preparation of 2-chloro-5-methylpyridine BAYER AKTIENGESELLSCHAFT (DE) 1990-01-30 US disclosed
EP-0324174-A2 Process for the preparation of 2-chloro-5-methylpyridine BAYER AG (DE) 1989-07-19 EP disclosed